[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596399":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":20,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":26,"sex":32,"minAge":33,"maxAge":10,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"Beijing Tsinghua Chang Gung Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Oteseconazole",null,"Subjects with SVVC will be treated with 600 mg (150 mg per capsule) on D1, 450 mg on D2",[13],"Drug: Oteseconazole (VT-1161) 150mg capsule",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Oteseconazole (VT-1161) 150mg capsule","Subjects with SVVC will be treated by Oteseconazole with 600 mg (150 mg per capsule) on D1, 450 mg on D2",[9],{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Qinping Liao","Chief physician","100596399","oteseconazole-in-the-treatment-of-adults-with-vulvovaginal-candidiasisvvc-100596399",false,"NCT07044947","Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）","Non-interventional Real-World Study of Oteseconazole in the Treatment of Vulvovaginal Candidiasis","VVC","Inclusion Criteria:\n\n* ≥ 18 years old, female; vulvovaginal signs and symptoms (VSS) score ≥7; Plan to use oteseconazole monotherapy or combination therapy\n\nExclusion Criteria:\n\n* Evidence has shown that the patient whohas been pregnant or lactating; Patients who are participating in or planning to participate in other interventional clinical studies; Other situations determined by the researcher as unsuitable for inclusion in the study","FEMALE","18 Years",{"count":35,"type":36},3000,"ESTIMATED","OBSERVATIONAL","Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51. Oteseconazole showed statistically significant and clinically meaningful treatment of severe VVC and was generally tolerated. The trial is a national multi-center, non-interventional observational real-world study, aiming to evaluate the effecacy and safety of oteseconazole in the treatment of patients with VVC. This study will include patients with severe vulvovaginal candidiasis (SVVC) . It is divided into prospective and retrospective parts.",[40],"Vulvovaginal Candidiasis","NOT_YET_RECRUITING","2025-06-23",{"date":44,"type":45},"2025-07-01","ACTUAL",{"date":47,"type":36},"2025-08-10",{"date":49,"type":36},"2030-08-10",{"name":5,"class":6}]